Loading...
Market
What will be the 5-year survival rate for advanced melanoma patients treated with combination immunotherapy by end of 2025?
2
Resolution / Starting Odds
Less than 50% • 25%
50-60% • 25%
60-70% • 25%
More than 70% • 25%
Clinical trial follow-up studies and publications
Story
CheckMate 067: Decade of Immunotherapy Advances Boosts Advanced Melanoma Survival to 72 Months
Sep 16, 2024, 12:30 PM
A decade of advancements in immunotherapy has significantly improved survival rates for patients with advanced melanoma. The CheckMate 067 trial revealed that the combination of nivolumab and ipilimumab resulted in a median overall survival of 72 months, compared to 37 months with nivolumab alone and 20 months with ipilimumab alone. The trial results were presented at the European Society for Medical Oncology (ESMO) 2024 conference. Merck presented 10-year follow-up data for their immunotherapy, highlighting the long-term benefits in metastatic melanoma survival. The medical community, including Weill Cornell, acknowledges the progress but emphasizes that further work is needed. The double drug treatment raises survival rate for half of advanced melanoma to 10 years.
View original story
Similar markets
Less than 50% • 25%
50% to 74% • 25%
75% to 80% • 25%
More than 80% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
